– The Telegraph
Oshkosh Slips On Q4 EPS Miss; Clocks 23% Top-Line Growth; Hikes Dividend
Oshkosh Corp (NYSE:OSK) reported fourth-quarter FY22 sales growth of 23% year-on-year to $2.20 billion, beating the consensus of $2.18 billion. Sales…
Related Posts
These Analysts Boost Their Forecasts On GitLab After Strong Q1 Results
GitLab Inc. (NASDAQ: GTLB) reported better-than-expected earnings results for its first quarter.
Getty Images Leverages NVIDIA’s Tech For Generative AI: Analyst Foresees Tangible 4Q Earnings Impact
Benchmark analyst Mark Zgutowicz reiterated a Buy rating on Getty Images Holdings, Inc. (NYSE: GETY),
ChromaDex New Published Phase II Clinical Study Demonstrates That Supplementation With Niagen, Patented Nicotinamide Riboside, Elevates NAD+ Up To Fourfold, Improving Motor Coordination And Eye Movement In Ataxia Telangiectasia Patients
This is the longest Niagen NR clinical trial to date spanning two years and showcases that long-term Niagen NR is safe and well toleratedStudy highlightsNR supplementation was well tolerated, with no serious adverse